CAMM News
Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice
SEARCH-TB demonstrates potential to be used as a highly granular pharmacodynamic assay that reveals antibiotic effects that are not apparent based on culture alone [Accepted in Antimicrobial Agents and Chemotherapy].
CAMM Investigators in collaboration with the Rapid Research in Diagnostics Development for TB (R2D2) Network launch The Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) Trial
CAMM Investigators in collaboration with the Rapid Research in Diagnostics Development for TB (R2D2) Network launch The Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) Trial. C3PO seeks to evaluate predictors of serious post-treatment outcomes among...
CAMM partners with MRI Global and The NIAID Mycobacterium tuberculosis Quality Assurance (TBQA) Program to support the external replication and validation of RS ratio®
CAMM partners with MRI Global and The NIAID Mycobacterium tuberculosis Quality Assurance (TBQA) Program to support the external replication and validation of RS ratio®.
CAMM collaborator Elizabeth Wynn, PhD joins National Jewish Health as Assistant Professor
CAMM collaborator Elizabeth Wynn, PhD joins National Jewish Health as Assistant Professor.
CAMM Molecular Core appoints Brandon Lamberson to serve as the General Supervisor for the CAMM Molecular Core’s new Laboratory
CAMM Molecular Core appoints Brandon Lamberson to serve as the General Supervisor for the CAMM Molecular Core’s new Laboratory at the Fitzsimons Innovation Community.
CAMM Molecular Core awarded $2.8 million from NIAID ACTG Lab Center
CAMM Molecular Core awarded $2.8 million from NIAID ACTG Lab Center to establish a state of the art CLIA lab in the Fitzsimons Innovation Community to support molecular assays for tuberculosis and other bacterial diseases.
Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis
CAMM evaluates new approach to evaluating single-drug and pairwise combinations showing promise for predicting the outcome of higher order drug combinations, paving the way for a more efficient approach to prioritizing large numbers of novel TB regimens for further...
Rada Savic, PhD, Co-PI of the Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium awarded $30.8M from the National Institute of Allergy and Infectious Diseases (NIAID)
Rada Savic, PhD, Co-PI of the Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium awarded $30.8M from the National Institute of Allergy and Infectious Diseases (NIAID). PReDicTR will establish a consortium of tuberculosis preclinical and...
Payam Nahid, MD, MPH, named executive director of UCSF’s Institute for Global Health Sciences
Payam Nahid, MD, MPH, named executive director of UCSF’s Institute for Global Health Sciences.
Transcriptional adaptation of Mycobacterium tuberculosis that survives prolonged multi-drug treatment in mice
SEARCH-TB elucidates effects of prolonged drug treatment on Mtb transcription in animal models, revealing adaptations distinct from those observed under environmental stress.
Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses
CAMM study using RS ratio® and CFU burden points to distinct Mtb phenotypes in various lung microenvironments highlighting the importance of joint utilization of PK and PD markers to identify drugs and combinations that optimally target Mtb populations.
CAMM receives $980,000 award from CRDF Global
CAMM receives $980,000 award from CRDF Global for RS ratio for measuring immune efficacy and bacterial physiology in TB April 2023